Turkdogan et al. suggest that CEA levels >500 ng/mL are a good marker for advanced disease and MTC mortality of up to 67%, while being more cost-effective than calcitonin and probably other markers [24]. The gene discussed is CEACAM5; the disease is medullary thyroid gland carcinoma.